Scholar Rock (SRRK) Expected to Announce Earnings on Wednesday

Key Points

• Scholar Rock is set to announce its Q2 2025 earnings on August 6, with analysts predicting an EPS of ($0.68), following a previous miss of expectations in May.
• Insider transactions show that key figures at Scholar Rock, including Mo Qatanani, sold significant shares, indicating a decrease in their ownership along with an overall trend of 93,654 shares sold by insiders in the past 90 days.
• Analysts have a consensus rating of "Buy" for Scholar Rock, with price targets ranging from $44.14 to $53.00, reflecting positive outlooks from several investment firms.

Scholar Rock (NASDAQ:SRRK - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.68) per share for the quarter.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.04). During the same period in the prior year, the business earned ($0.59) earnings per share. On average, analysts expect Scholar Rock to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Scholar Rock Stock Performance

Shares of SRRK opened at $36.36 on Monday. The stock has a 50-day moving average of $35.27 and a two-hundred day moving average of $34.73. Scholar Rock has a one year low of $6.76 and a one year high of $46.98. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.25 and a current ratio of 10.25. The stock has a market cap of $3.45 billion, a P/E ratio of -14.37 and a beta of 0.48.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on SRRK shares. Wedbush reiterated an "outperform" rating and set a $50.00 price target on shares of Scholar Rock in a research report on Wednesday, June 18th. Lifesci Capital upgraded Scholar Rock to a "strong-buy" rating in a research report on Tuesday, June 3rd. Raymond James Financial set a $53.00 target price on Scholar Rock and gave the company a "strong-buy" rating in a report on Wednesday, July 30th. Finally, Cantor Fitzgerald initiated coverage on Scholar Rock in a report on Thursday, July 17th. They set an "overweight" rating for the company. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Scholar Rock has a consensus rating of "Buy" and an average target price of $44.14.

Insider Activity

In other news, Director Jeffrey S. Flier sold 20,316 shares of the business's stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $32.24, for a total transaction of $654,987.84. Following the sale, the director owned 24,070 shares of the company's stock, valued at $776,016.80. The trade was a 45.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kristina Burow sold 5,400 shares of the company's stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $29.72, for a total value of $160,488.00. Following the completion of the sale, the director directly owned 21,071 shares in the company, valued at approximately $626,230.12. The trade was a 20.40% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 93,654 shares of company stock valued at $3,101,811. Insiders own 13.30% of the company's stock.

Hedge Funds Weigh In On Scholar Rock

Hedge funds have recently bought and sold shares of the company. Strs Ohio acquired a new position in shares of Scholar Rock during the first quarter valued at approximately $77,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Scholar Rock by 12.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company's stock valued at $1,709,000 after acquiring an additional 5,831 shares during the period. AQR Capital Management LLC increased its stake in shares of Scholar Rock by 609.3% during the first quarter. AQR Capital Management LLC now owns 57,294 shares of the company's stock valued at $1,842,000 after acquiring an additional 49,217 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Scholar Rock by 25.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company's stock valued at $5,460,000 after acquiring an additional 34,594 shares during the period. Finally, Millennium Management LLC increased its stake in shares of Scholar Rock by 37.4% during the first quarter. Millennium Management LLC now owns 200,255 shares of the company's stock valued at $6,438,000 after acquiring an additional 54,555 shares during the period. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.